0001104659-23-106441.txt : 20231003 0001104659-23-106441.hdr.sgml : 20231003 20231003165945 ACCESSION NUMBER: 0001104659-23-106441 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231003 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231003 DATE AS OF CHANGE: 20231003 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVAVAX INC CENTRAL INDEX KEY: 0001000694 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222816046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26770 FILM NUMBER: 231304994 BUSINESS ADDRESS: STREET 1: 700 QUINCE ORCHARD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 240-268-2000 MAIL ADDRESS: STREET 1: 700 QUINCE ORCHARD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 8-K 1 tm2327587d1_8k.htm FORM 8-K
0001000694 false 0001000694 2023-10-03 2023-10-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 3, 2023

 

 

NOVAVAX, INC.

(Exact name of registrant as specified in charter)  

 

 

Delaware   0-26770   22-2816046

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

700 Quince Orchard Road

Gaithersburg, Maryland 20878

(Address of Principal Executive Offices, including Zip Code)

 

(240) 268-2000

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

  

Title of each class   Trading
Symbol(s)		   Name of each exchange on which
registered
Common Stock, Par Value $0.01 per share   NVAX   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On October 3, 2023, Novavax, Inc. (the “Company”) issued a press release announcing that the Company’s Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (“NVX-CoV2601”) has received Emergency Use Authorization from the U.S. Food and Drug Administration for active immunization to prevent COVID-19 in individuals aged 12 and older. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

 

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated October 3, 2023.
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NOVAVAX, INC.
     
     
Date: October 3, 2023 By: /s/ John A. Herrmann III
  Name: John A. Herrmann III
  Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

 

 

 EX-99.1 2 tm2327587d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

   
Press Release  

 

  

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

 

·This Emergency Use Authorization and CDC recommendation makes Novavax’s vaccine the only protein-based non-mRNA COVID vaccine option in the U.S.
·Novavax expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid
·Find Novavax’s vaccine at us.novavaxcovidvaccine.com or vaccines.gov

  

GAITHERSBURG, Md., October 3, 2023 – Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older. Immediately upon authorization, Novavax’s vaccine has also been included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on September 12, 2023.

 

Doses will be available nationwide at thousands of locations, including national and local retail pharmacies and physicians’ offices, following the Center for Biologics Evaluation and Research release of vaccine batches, expected in the coming days.

 

“COVID-19 is once again on the rise with infections and hospitalizations increasing, so it’s important that individuals get vaccinated to protect themselves and their loved ones,” said John C. Jacobs, President and Chief Executive Officer, Novavax. “Novavax’s authorization today means people will now have the choice of a protein-based non-MRNA option to help protect themselves against COVID-19, which is now the fourth leading cause of death in the U.S. In the coming days, individuals in the U.S. can go to pharmacies, physicians’ offices, clinics and various government entities to receive an updated Novavax vaccine.”

 

The EUA was based on non-clinical data showing that Novavax’s COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax’s vaccine induced neutralizing antibody responses to newly emerging subvariants BA.2.86, EG.5.1 FL.1.5.1 and XBB.1.16.6 as well as robust CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax’s vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants.1,2

 

In clinical trials, the most common adverse reactions associated with Novavax’s prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise.

 

The EUA aligns with globally harmonized guidance from the FDA, European Medicines Agency and the World Health Organization to target the XBB strain this fall.3-5 Novavax is working with these and other global regulatory authorities on authorizations for its vaccine.

 

 

 

 

AUTHORIZED USE IN THE U.S.

 

Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. Refer to the full Fact Sheet for information about the Novavax COVID-19 Vaccine, Adjuvanted.

 

The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

  

IMPORTANT SAFETY INFORMATION

 

What should you mention to your vaccination provider before you or your child get the Novavax COVID-19 Vaccine, Adjuvanted?

 

Tell your vaccination provider about all of your or your child’s medical conditions, including if you or your child:

 

·have any allergies
·have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)
·have a fever
·have a bleeding disorder or are on a blood thinner
·are immunocompromised or are on a medicine that affects your immune system
·are pregnant or plan to become pregnant
·are breastfeeding
·have received another COVID-19 vaccine
·have ever fainted in association with an injection

  

Who should not get the Novavax COVID-19 Vaccine, Adjuvanted?

 

A person should not get the Novavax COVID-19 Vaccine, Adjuvanted if they had:

 

·a severe allergic reaction after a previous dose of any Novavax COVID-19 Vaccine, Adjuvanted
·a severe allergic reaction to any ingredient of these vaccines

  

What are the risks of the Novavax COVID-19 Vaccine, Adjuvanted?

 

There is a remote chance that the vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose. For this reason, the vaccination provider may ask you or your child to stay at the place where you or your child received the vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:

 

·Difficulty breathing
·Swelling of the face and throat
·A fast heartbeat
·A bad rash all over your body
·Dizziness and weakness

  

  2

 

 

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within 10 days following vaccination. The chance of having this occur is very low. You should seek medical attention right away if you or your child have any of the following symptoms after receiving the vaccine:

 

·Chest pain
·Shortness of breath
·Feelings of having a fast-beating, fluttering, or pounding heart

  

Side effects that have been reported in clinical trials with the Novavax COVID-19 Vaccine, Adjuvanted include:

 

·Myocarditis (inflammation of the heart muscle)
·Pericarditis (inflammation of the lining outside the heart)
·Injection site reactions: pain/tenderness, swelling, redness and itching
·General side effects: fatigue or generally feeling unwell, muscle pain, headache, joint pain, nausea, vomiting, fever, chills
·Allergic reactions such as hives and swelling of the face
·Swollen lymph nodes

  

Side effects that have been reported in post-authorization use with the Novavax COVID-19 Vaccine, Adjuvanted include:

 

·Severe allergic reactions
·Myocarditis (inflammation of the heart muscle)
·Pericarditis (inflammation of the lining outside the heart)
·Paresthesia (unusual feeling in the skin such as tingling or a crawling feeling)
·Hypoesthesia (decreased feeling or sensitivity, especially in the skin)

  

These may not be all the possible side effects. Serious and unexpected side effects may occur. The possible side effects are still being studied.

  

What should I do about side effects?

 

If you or your child experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

 

Call the vaccination provider or your healthcare provider for any side effects that bother you or your child or do not go away.

 

Report vaccine side effects to the FDA and the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to https://vaers.hhs.gov/reportevent.html. Please include “Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) EUA” in the first line of box #18 of the report form.

 

 

  3

 

 

In addition, you can report side effects to Novavax, Inc., using the following contact information: Website: www.NovavaxMedInfo.com, Fax Number: 1-888-988-8809, Telephone Number: 1-844-NOVAVAX (1-844-668-2829).

 

What about pregnancy or breastfeeding?

 

If you or your child are pregnant or breastfeeding, discuss the options with your healthcare provider.

 

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to the Novavax COVID-19 Vaccine, Adjuvanted during pregnancy. Women who are vaccinated with the Novavax COVID-19 Vaccine, Adjuvanted during pregnancy are encouraged to enroll in the registry by visiting https://c-viper.pregistry.com.

 

Please see the Fact Sheet for Recipients and Caregivers for more information. Reporting Adverse Events and Vaccine Administration Errors

 

·Adverse events can also be reported to Novavax, Inc. using the following contact information or by providing a copy of the VAERS form to Novavax, Inc. Website: https://www.novavaxmedinfo.com/, Fax Number: 1-888-988-8809, Telephone Number: 1-844-NOVAVAX (1-844-668-2829).

 

About Novavax

 

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world’s most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.

 

Forward-Looking Statements

 

Statements herein relating to the future of Novavax, its operating plans and prospects, the scope, timing and outcome of future regulatory filings and actions, including the availability of its updated XBB version of its Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) and the timing of delivery and distribution of its vaccine are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory authorization for its product candidates, including its updated XBB version of its COVID-19 vaccine in time for the fall 2023 vaccination season or for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax’s exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; challenges in obtaining commercial adoption of our updated protein-based non-mRNA XBB COVID-19 vaccine, NVX-CoV2373 or any COVID-19 variant strain-containing formulation; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

 

  4

 

 

Contacts:

Investors

Erika Schultz

240-268-2022

ir@novavax.com

 

Media

Ali Chartan

240-720-7804

media@novavax.com

 

References

1.Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. Science. 2022;377(6608):821-822. doi:10.1126/science.add2897.
2.Markov PV, Ghafari M, Beer M, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21(6):361-379. doi:10.1038/s41579-023-00878-2.
3.U.S. Food and Drug Administration (FDA). Updated COVID-19 vaccines for use in the United States beginning in fall 2023. June 16, 2023. https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023.
4.European Medicines Agency (EMA). EMA and ECDC statement on updating COVID-19 vaccines to target new SARS-CoV-2 virus variants. June 6, 2023. https://www.ema.europa.eu/en/news/ema-ecdc-statement-updating-covid-19-vaccines-target-new-sars-cov-2-virus-variants.
5.World Health Organization (WHO). XBB.1.5 updated risk assessment. June 20, 2023. https://www.who.int/docs/default-source/coronaviruse/20230620xbb.1.5.pdf?sfvrsn=fff6f686_3.

 

 

  5

 EX-101.SCH 3 nvax-20231003.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nvax-20231003_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nvax-20231003_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2327587d1_img1.jpg GRAPHIC begin 644 tm2327587d1_img1.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 03, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 03, 2023
Entity File Number 0-26770
Entity Registrant Name NOVAVAX, INC.
Entity Central Index Key 0001000694
Entity Tax Identification Number 22-2816046
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 700 Quince Orchard Road
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20878
City Area Code 240
Local Phone Number 268-2000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.01 per share
Trading Symbol NVAX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2327587d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001000694 2023-10-03 2023-10-03 iso4217:USD shares iso4217:USD shares 0001000694 false 8-K 2023-10-03 NOVAVAX, INC. DE 0-26770 22-2816046 700 Quince Orchard Road Gaithersburg MD 20878 240 268-2000 false false false false Common Stock, Par Value $0.01 per share NVAX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://novavax.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nvax-20231003.xsd nvax-20231003_lab.xml nvax-20231003_pre.xml tm2327587d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2327587d1_8k.htm": { "nsprefix": "nvax", "nsuri": "http://novavax.com/20231003", "dts": { "schema": { "local": [ "nvax-20231003.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nvax-20231003_lab.xml" ] }, "presentationLink": { "local": [ "nvax-20231003_pre.xml" ] }, "inline": { "local": [ "tm2327587d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://novavax.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2327587d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2327587d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-106441-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-106441-xbrl.zip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end